INS and Hyperglycemia: In patients with T2DM, exenatide slowed gastric emptying; reduced fasting hyperglycemia and hyperglucagonemia; stimulated glucose-dependent insulin secretion (pancreatic β-cell function); attenuated post-prandial excursions of glucose, insulin, and glucagon; inhibited food intake; and reduced body weight.